Reports
Japanese opportunity for biosimilars
Japan is proving to be a favourable market for biosimilars, with more than half a billion dollars worth in sales waiting for prospective makers of biosimilars.
Brand-name discount cards increase private insurance spending in Canada
The use of brand-name discount cards, designed to help patients save money, increase private insurance expenditure by almost 50%, finds a study published in the Canadian Medical Association Journal [1].
EC workshop on biosimilars focusses on sustainability
The European Commission (EC) held its fifth workshop on biosimilars in Brussels, Belgium on 30 October 2019. The focus of this workshop was the sustainability of the biosimilar medicines sector [1].
How to support a viable US biosimilars market
In a previous article Ms Juliana Reed, President of the Biosimilars Forum, outlined why the US biosimilars market is sluggish at the DIA Biosimilars Conference, which was held on 23‒24 September 2019 in Bethesda, Maryland, USA [1].
The sluggish US biosimilars market
Juliana Reed, President of the Biosimilars Forum, gave a presentation on ‘The State of the Biosimilars Market’ at the Drug Information Association’s (DIA) Biosimilars Conference, which was held on 23-24 September 2019 in Bethesda, Maryland, USA [1].
Varied approach to interchangeability across the MENA region
To achieve global agreement on issues of regulatory approval of biosimilars, open discussion across national borders and between different stakeholder groups is key. A lack of agreement between countries that make up the Middle East and North Africa (MENA) region, particularly in the area of interchangeability and switching, was made clear at a meeting organized by the Generics and Biosimilars Initiative (GaBI).
Designing fit-for-purpose biosimilar studies
The design of biosimilar studies that are fit for purpose was discussed by Dr Jaclyn Bosco of IQVIA through the presentation on ‘Biosimilar considerations for real world research and stakeholder questions’ [1].
Uptake of biosimilars in different countries varies
The uptake of biosimilars in different countries was a subject discussed by both Dr Jaclyn Bosco and Mr Murray Aitken of IQVIA.
Biosimilar regulation in the Middle East
The Generics and Biosimilars Initiative’s second Middle East and North Africa (MENA) Stakeholder Meeting on Regulatory Approval, Clinical Settings, Interchangeability and Pharmacovigilance of Biosimilars [1] opened with an introduction to United Arab Emirates’ (UAE) National Strategy for Innovation.
Considerations for real-world research on biosimilars
In a presentation on ‘Biosimilar Considerations for Real World Research and Stakeholder Questions’ at the Drug Information Association’s (DIA) Biosimilars Conference, which was held on 23‒24 September 2019 in Bethesda, Maryland, USA, considerations for real-world research on biosimilars were discussed by Dr Jaclyn Bosco of IQVIA. These include:
